Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- ribonucleic acid
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 294648
For the Research License, Licensor grants a non-exclusive, world-wide license, without the right to sublicense, under the Licensor Existing IP and the Joint Program IP, to perform the Joint Research Program and the Joint Development Program.
Licensor Products means Products and Drug Products for the treatment of human diseases other than cancer.
IPSCIO Record ID: 294282
For the Research License, Licensor grants a non-exclusive, world-wide license, without the right to sublicense, under the Licensor Existing IP and the Joint Program IP, to perform the Joint Research Program and the Joint Development Program.
Technology is for the development and manufacture of siRNA molecules silencing gene targets in animals and humans, and the preparation of (liposome-based) formulations for the delivery of siRNA therapeutic products, as well as any and all intellectual property rights therein, including without limitation Patent Rights, copyright, trademark or trade secret rights.
Licensor Program IP means certain stabilized, chemically modified siRNA molecule(s) silencing the human 801 gene and the mouse 801 gene that have been developed by Licensor prior to the date of this Agreement and certain lipids and liposome-based formulations.
IPSCIO Record ID: 294284
For the License, upon exercise of each specific option the German Licensor shall grant a non-exclusive license under German IP in accordance with the terms and conditions specified. Licensor agrees to grant a non-exclusive and worldwide license with the right to sub-license at terms and conditions consistent with this Agreement under the Licensor IP and the know-how relating to the atuRNAi(s) to research, develop, have developed, manufacture, have manufactured, market and sell Licensee Products.
atuRNAi(s) shall mean the siRNAs developed by or for Licensor and supplied to Licensee under this Agreement as potential inhibitors of certain molecular drug targets for therapeutic intervention.
Licensee IP means the present and future Patent Rights and Know-How owned by Licensee and directed to the [polypeptides, to nucleic acids encoding the polypeptides, antibodies to the polypeptides, antisense and siRNAJ to the Licensee Target genes and methods of treatment of diseases using these, including but not limited to rights to patents and patent applications.
Licensee Products means Products and Drug Products for the treatment of human diseases covered by Licensee IP.
The property includes Patent application EP 04010700.05 describing the use of lipids in formulations to deliver oligonucleotides into cells and tissues and all equivalent and derived applications including EP 02017601.2], and, PCT application number WO 2004/015107 and all equivalent/derived applications including US Provisional Application 60/402,541, the Licensors core technology patent application.
Oxidative stress is an imbalance between free radicals and antioxidants in your body. Free radicals are oxygen-containing molecules with an uneven number of electrons. The uneven number allows them to easily react with other molecules.
Ischemic injury is caused by diminished or absent blood flow. The main mechanism of injury in ischemia is hypoxia (as described above).
IPSCIO Record ID: 332237
6,579,520 – IL-17 related mammalian cytokine polypeptides (IL-17E)
6,569,645 – IL-17 homologous polypeptides and therapeutic uses thereof
Licensee Protein means a IL-17E protein for which either (a) the research and/or at least one Clinical Trial was significantly conducted by Licensee either on its own, or together and in
collaboration with a Sublicensee or (b) Licensee and/or its Sublicensees have exclusive marketing rights worldwide.
